Lantheus Holdings, Inc. Restricted Cash and Cash Equivalents
Lantheus Holdings, Inc. (LNTH) had Restricted Cash and Cash Equivalents of $1.72 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-06
- 2026-06-30: Restricted Cash and Cash Equivalents $1.72M.
- 2026-03-31: Restricted Cash and Cash Equivalents $1.71M.
- 2025-12-31: Restricted Cash and Cash Equivalents $1.71M.
- 2025-09-30: Restricted Cash and Cash Equivalents $1.70M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.71M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.71M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.69M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $1.68M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $1.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.66M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $1.65M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $1.64M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $1.63M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.62M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $1.61M 10-Q · filed 2024-07-31 |
| 2023-03-31 | $1.60M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $1.59M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.58M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $2.14M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $2.14M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $2.14M 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.14M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $2.14M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $2.14M 10-Q · filed 2022-04-29 |
| 2020-12-31 | $2.14M 10-K · filed 2023-02-23 |
| 2020-09-30 | $2.14M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $2.14M 10-Q · filed 2021-07-28 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-31 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |